Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

Hsien Tzung Liao, Yuh Feng Lin, Chang Youh Tsai, Chung Tei Chou

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: The aim of this study was to investigate the role of regulatory T cells (Tregs) in ankylosing spondylitis (AS). Methods: We included 69 AS patients (15 of them received anti-tumor necrosis factor-apha agent-adalimumab) in the study and used a questionnaire to record the demographic data, disease activity index, functional index, human leukocyte antigen-B27, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Thirty healthy subjects were used as controls. The peripheral blood mononuclear cells (PMBCs) were stained with anti-CD4, anti-CD25 and anti-Forkhead/winged helix transcription factor P3 (anti-FoxP3) antibodies and flow-cytometry was used to determine cell populations. Results: The percentages of Tregs in PMBCs were significantly higher in AS patients than in healthy controls. In AS patients who had poor disease functional index with higher levels of ESR and CRP were positively and significantly correlated with Tregs percentages in PMBCs. After adalimumab treatment in 15 patients, the percentages of Tregs, the ESR/CRP levels and the Bath Ankylosing Spondylitis Disease Activity Index/Bath Ankylosing Spondylitis Functional Index were significantly and gradually decreased over time. Conclusions: The high expression of FoxP3 and CD25 on CD4+ T cells in PBMCs in AS patients was noted, and could be reversed by adalimumab therapy. These findings suggest that Tregs may play a role in modulating the inflammatory process in AS. Whether Tregs can be taken as a predictor for disease activity or treatment outcome is unclear and requires further study.

Original languageEnglish
Pages (from-to)423-427
Number of pages5
JournalJoint Bone Spine
Volume82
Issue number6
DOIs
Publication statusPublished - 2015

Fingerprint

Ankylosing Spondylitis
Regulatory T-Lymphocytes
Blood Sedimentation
C-Reactive Protein
Therapeutics
Baths
Winged-Helix Transcription Factors
Adalimumab
HLA Antigens
Blood Cells
Healthy Volunteers
Flow Cytometry
Tumor Necrosis Factor-alpha
Demography
T-Lymphocytes
Antibodies
Population

Keywords

  • Ankylosing spondylitis
  • Regulatory T cells (Tregs)
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Rheumatology

Cite this

Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment. / Liao, Hsien Tzung; Lin, Yuh Feng; Tsai, Chang Youh; Chou, Chung Tei.

In: Joint Bone Spine, Vol. 82, No. 6, 2015, p. 423-427.

Research output: Contribution to journalArticle

Liao, Hsien Tzung ; Lin, Yuh Feng ; Tsai, Chang Youh ; Chou, Chung Tei. / Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment. In: Joint Bone Spine. 2015 ; Vol. 82, No. 6. pp. 423-427.
@article{a6aae21be6c040eeb2be1c58095259a6,
title = "Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment",
abstract = "Objectives: The aim of this study was to investigate the role of regulatory T cells (Tregs) in ankylosing spondylitis (AS). Methods: We included 69 AS patients (15 of them received anti-tumor necrosis factor-apha agent-adalimumab) in the study and used a questionnaire to record the demographic data, disease activity index, functional index, human leukocyte antigen-B27, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Thirty healthy subjects were used as controls. The peripheral blood mononuclear cells (PMBCs) were stained with anti-CD4, anti-CD25 and anti-Forkhead/winged helix transcription factor P3 (anti-FoxP3) antibodies and flow-cytometry was used to determine cell populations. Results: The percentages of Tregs in PMBCs were significantly higher in AS patients than in healthy controls. In AS patients who had poor disease functional index with higher levels of ESR and CRP were positively and significantly correlated with Tregs percentages in PMBCs. After adalimumab treatment in 15 patients, the percentages of Tregs, the ESR/CRP levels and the Bath Ankylosing Spondylitis Disease Activity Index/Bath Ankylosing Spondylitis Functional Index were significantly and gradually decreased over time. Conclusions: The high expression of FoxP3 and CD25 on CD4+ T cells in PBMCs in AS patients was noted, and could be reversed by adalimumab therapy. These findings suggest that Tregs may play a role in modulating the inflammatory process in AS. Whether Tregs can be taken as a predictor for disease activity or treatment outcome is unclear and requires further study.",
keywords = "Ankylosing spondylitis, Regulatory T cells (Tregs), Tumor necrosis factor-α",
author = "Liao, {Hsien Tzung} and Lin, {Yuh Feng} and Tsai, {Chang Youh} and Chou, {Chung Tei}",
year = "2015",
doi = "10.1016/j.jbspin.2015.03.003",
language = "English",
volume = "82",
pages = "423--427",
journal = "Revue du Rhumatisme (English Edition)",
issn = "1169-8446",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

AU - Liao, Hsien Tzung

AU - Lin, Yuh Feng

AU - Tsai, Chang Youh

AU - Chou, Chung Tei

PY - 2015

Y1 - 2015

N2 - Objectives: The aim of this study was to investigate the role of regulatory T cells (Tregs) in ankylosing spondylitis (AS). Methods: We included 69 AS patients (15 of them received anti-tumor necrosis factor-apha agent-adalimumab) in the study and used a questionnaire to record the demographic data, disease activity index, functional index, human leukocyte antigen-B27, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Thirty healthy subjects were used as controls. The peripheral blood mononuclear cells (PMBCs) were stained with anti-CD4, anti-CD25 and anti-Forkhead/winged helix transcription factor P3 (anti-FoxP3) antibodies and flow-cytometry was used to determine cell populations. Results: The percentages of Tregs in PMBCs were significantly higher in AS patients than in healthy controls. In AS patients who had poor disease functional index with higher levels of ESR and CRP were positively and significantly correlated with Tregs percentages in PMBCs. After adalimumab treatment in 15 patients, the percentages of Tregs, the ESR/CRP levels and the Bath Ankylosing Spondylitis Disease Activity Index/Bath Ankylosing Spondylitis Functional Index were significantly and gradually decreased over time. Conclusions: The high expression of FoxP3 and CD25 on CD4+ T cells in PBMCs in AS patients was noted, and could be reversed by adalimumab therapy. These findings suggest that Tregs may play a role in modulating the inflammatory process in AS. Whether Tregs can be taken as a predictor for disease activity or treatment outcome is unclear and requires further study.

AB - Objectives: The aim of this study was to investigate the role of regulatory T cells (Tregs) in ankylosing spondylitis (AS). Methods: We included 69 AS patients (15 of them received anti-tumor necrosis factor-apha agent-adalimumab) in the study and used a questionnaire to record the demographic data, disease activity index, functional index, human leukocyte antigen-B27, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Thirty healthy subjects were used as controls. The peripheral blood mononuclear cells (PMBCs) were stained with anti-CD4, anti-CD25 and anti-Forkhead/winged helix transcription factor P3 (anti-FoxP3) antibodies and flow-cytometry was used to determine cell populations. Results: The percentages of Tregs in PMBCs were significantly higher in AS patients than in healthy controls. In AS patients who had poor disease functional index with higher levels of ESR and CRP were positively and significantly correlated with Tregs percentages in PMBCs. After adalimumab treatment in 15 patients, the percentages of Tregs, the ESR/CRP levels and the Bath Ankylosing Spondylitis Disease Activity Index/Bath Ankylosing Spondylitis Functional Index were significantly and gradually decreased over time. Conclusions: The high expression of FoxP3 and CD25 on CD4+ T cells in PBMCs in AS patients was noted, and could be reversed by adalimumab therapy. These findings suggest that Tregs may play a role in modulating the inflammatory process in AS. Whether Tregs can be taken as a predictor for disease activity or treatment outcome is unclear and requires further study.

KW - Ankylosing spondylitis

KW - Regulatory T cells (Tregs)

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=84961918691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961918691&partnerID=8YFLogxK

U2 - 10.1016/j.jbspin.2015.03.003

DO - 10.1016/j.jbspin.2015.03.003

M3 - Article

C2 - 26188878

AN - SCOPUS:84961918691

VL - 82

SP - 423

EP - 427

JO - Revue du Rhumatisme (English Edition)

JF - Revue du Rhumatisme (English Edition)

SN - 1169-8446

IS - 6

ER -